Print version

pdf Click to download

Search Pub Med

038P University of Leicester, UK
6th Focused Meeting on Cell Signalling



Desensitisation of the long chain fatty acid receptors FFA1 and FFA4

SZ Raihan, A Inoue, G Milligan

The G protein-coupled receptors FFA1 (GPR40) and FFA4 (GPR120) are very attractive targets for drug development for the treatment of both various metabolic disorders, specifically type-2 diabetes, and inflammatory conditions (1). Both receptors are coupled to Gq/11 and β-arrestin mediated pathways, which interact to influence systemic metabolic function in physiological and pathophysiological conditions (2). Following agonist binding, these receptors are phosphorylated by members of the G protein-coupled receptor kinases (GRK) family and also potentially by protein kinase C. Such effects frequently allow for recruitment of β-arrestins, receptor internalisation, and desensitisation. Agonist activation of these receptors can result in rapid desensitisation (3); however, mechanisms responsible are yet to be fully elucidated.

Herein, human FFA1 and FFA4 receptors were expressed in both HEK293 cells and in modified HEK293 cell lines, generated by CRISPR-Cas9-mediated genome editing (4), that lacked expression of either Gq/11 or β-arrestin1/2 proteins as determined by immunoblot analysis. In cells lacking Gq/11 selective agonists of either FFA1 (TUG-905) or FFA4 (TUG891) receptors failed to produce responses in cell population or single cell calcium imaging studies. This was also the case in myo-inositol-1-phosphate (IP1) accumulation assays. However, such signals were regained when Gq alpha protein was re-introduced into the Gq/11 knockout cell lines.

Experiments in β-arrestin1/2 knockout cells demonstrated that lack of these arrestins did not prevent rapid agonist-mediated desensitisation of either FFA1 or FFA4 and that both receptors were as capable of elevating [Ca2+]i in these cells as in the parental cell lines. These results suggest that non β-arrestin- mediated pathways are likely involved in the desensitisation process.

Although both FFA1 and FFA4 are able to engage β-arrestins in an agonist-dependent manner, maintained rapid desensitisation in the absence of β-arrestins indicates potential roles of a second messenger-dependent kinase, e.g. protein kinase C in the regulation of signalling and function of these receptors (5) and this could help better understanding the desensitisation of these important therapeutic targets.

(1) Milligan G et al. (2015). Br J Pharmacol. 13:3254–3265;

(2) Moran BM et al. (2016) Acta Diabetol. [Epub ahead of print] PMID: 26739335;

(3) Hudson BD et al. (2013). Mol Pharmacol. 5:710–725;

(4) Schrage R et al. (2015). Nat Commun. 6:10156;

(5) Sosa-Alvarado C et al. (2015) Eur J. Pharmacol. 768, 108–115.